Skip to main content
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. — Investor Relations & Filings

Ticker · AVTX ISIN · US05338F1084 LEI · 549300GPK6FPJ3X8SZ39 US Professional, scientific and technical activities
Filings indexed 1,067 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country US United States of America
Listing US AVTX

About Avalo Therapeutics, Inc.

https://www.avalotx.com/

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for immune-mediated inflammatory diseases. The company's strategy is centered on advancing novel therapies that target the interleukin-1 beta (IL-1β) pathway. Its lead asset, AVTX-009, is an IL-1β monoclonal antibody currently in a Phase 2 clinical trial for the treatment of hidradenitis suppurativa (HS). Avalo Therapeutics is also exploring the application of its IL-1β-based approach for other prevalent inflammatory conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
Regulatory Filings
2026-04-28 English
DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)
Proxy Solicitation & Information Statement
2026-04-10 English
S-8 - Avalo Therapeutics, Inc. (0001534120) (Filer)
Registration Form
2026-03-23 English
10-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
Annual Report
2026-03-23 English
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
Regulatory Filings
2026-03-23 English
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
Director's Dealing
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.